Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice

Vaccine
Chen-Yi ChiangHsin-Wei Chen

Abstract

The linkage of an immunogen with a toll-like receptor ligand has great potential to induce highly potent immune responses with the initial features of antigen-presenting cell activation. In the current study, we expressed recombinant dengue-3 envelope protein domain III (D3ED III) in lipidated form using an Escherichia coli-based system. The recombinant lipidated dengue-3 envelope protein domain III (LD3ED III) augments the expression levels of IL-12 family cytokines. LD3ED III-immunized mice enhance wide ranges of T cell responses as indicated by IFN-γ, IL-17, IL-21 production. Additionally, LD3ED III-immunized mice increase the frequencies of anti-D3ED III antibody producing cells. The boosted antibody titers cover various IgG isotypes, including IgG1, IgG2a, IgG2b, and IgG3. Importantly, LD3ED III-immunized mice induce neutralizing antibody capacity associated with a reduction of viremia levels after challenges. In contrast, mice that are immunized with D3ED III formulated with aluminum phosphate (D3ED III/Alum) only enhance Th2 responses and boost IgG1 antibody titers. Neither neutralizing antibody responses nor the inhibition of viremia levels after challenge is observed in mice that are immunized with D3ED III/Alum. These...Continue Reading

References

Nov 26, 2002·Science·Katsutoshi OzakiWarren J Leonard
Dec 4, 2002·Nature Reviews. Immunology·Kenneth M Murphy, Steven L Reiner
Mar 18, 2005·Annual Review of Immunology·Louise J McHeyzer-Williams, Michael G McHeyzer-Williams
Feb 21, 2006·Nature·J Magarian Blander, Ruslan Medzhitov
Dec 31, 2008·Microbes and Infection·Chih-Hsiang LengHsin-Wei Chen
Jan 30, 2010·Expert Review of Vaccines·Maria G GuzmanGerardo Guillén
Feb 10, 2010·The Journal of Experimental Medicine·Michelle A LintermanCarola G Vinuesa
Feb 10, 2010·The Journal of Experimental Medicine·Dimitra ZotosDavid M Tarlinton
Nov 17, 2010·Nature Reviews. Microbiology·Maria G GuzmanRosanna W Peeling
Nov 26, 2010·The Journal of Experimental Medicine·Marcel BattenNico Ghilardi
Apr 26, 2011·Current Opinion in Immunology·Beth-Ann G Coller, David E Clements
Aug 10, 2011·PloS One·Chen-Yi ChiangHsin-Wei Chen
Apr 17, 2012·Immunological Reviews·Mark J Shlomchik, Florian Weisel
Jul 21, 2012·Nature Immunology·Dario A A Vignali, Vijay K Kuchroo
Aug 11, 2012·PLoS Neglected Tropical Diseases·Oliver J BradySimon I Hay
Aug 2, 2013·Journal of Leukocyte Biology·Markus Bosmann, Peter A Ward
Mar 7, 2014·Frontiers in Immunology·Leen Moens, Stuart G Tangye
Nov 5, 2014·The New England Journal of Medicine·Luis VillarUNKNOWN CYD15 Study Group

❮ Previous
Next ❯

Citations

Feb 23, 2018·Applied Microbiology and Biotechnology·Hossein FahimiMajid Sadeghizadeh
Sep 8, 2018·Frontiers in Immunology·Nagesh K Tripathi, Ambuj Shrivastava
Apr 8, 2020·Frontiers in Cellular and Infection Microbiology·Kaihao FengJing An
Jun 13, 2017·Microbiology and Immunology·Nattika NantachitSukathida Ubol
Feb 7, 2020·Vaccines·Sheng-Qun DengHong-Juan Peng
Jun 30, 2021·Expert Review of Anti-infective Therapy·Chung-Hao HuangYen-Hsu Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.